Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Privosegtor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Privosegtor | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Privosegtor | DRUG | Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days |
| Methylprednisolone | DRUG | Methylprednisolone 1 g/day IV for 5 treatment days |
| Placebo | OTHER | 0.9% sodium chloride (NaCl) solution IV for 5 treatment days |
Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a hist...
Privosegtor is an investigational small molecule being developed for the treatment of optic neuritis, a condition involving inflammation of the optic nerve. It is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.
Privosegtor targets SGK2, a serum and glucocorticoid-regulated kinase. By modulating this molecular target, the drug is being studied for its potential therapeutic effect in optic neuritis. The exact mechanism of action is under investigation in clinical trials.
Privosegtor is being developed by Oculis Holding AG, a biopharmaceutical company listed on the stock exchange under the ticker symbol OCS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with optic neuritis.
Privosegtor is currently in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Breakthrough Therapy designation, Orphan Drug designation, and Priority Review designation by the FDA.
Privosegtor is being evaluated in a Phase 3 clinical trial with the identifier NCT07623668. This randomized, double-blind, placebo-controlled study is recruiting approximately 210 participants with optic neuritis in the United States. The trial is currently active and enrolling patients aged 18 years and older.
Privosegtor is the sole name provided for this investigational drug. No alternative names or brand names have been associated with it in the available information. It is being studied under this name in clinical trials for optic neuritis.